SGLT2 inhibitors and autophagy in diabetes
Cell Biochemistry and Function · 2023-06 · 41 (4) · 392-398
DOI: 10.1002/cbf.3792 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, online erschienen am 10.04.2023. Verfasst von Habib Yaribeygi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hyperglycemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Autophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications. Therefore, autophagy‐modifying therapy may be of value to prevent the development of complications. Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs that achieve normoglycemia through causing overt glycosuria. There is evidence that these drugs may have pleiotropic extra‐glycemic benefits, but their effect on the autophagy process is unclear; therefore, this review was undertaken to clarify the possible effects of SGLT2is on autophagy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
- Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Busaiteen, Bahrain.
- Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID-Profile: Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Amirhossein Sahebkar
Zitieren
APA
Yaribeygi, H., Maleki, M., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2023). SGLT2 inhibitors and autophagy in diabetes. Cell Biochemistry and Function, 41(4), 392-398. https://doi.org/10.1002/cbf.3792
Vancouver
Yaribeygi H, Maleki M, Atkin SL, Jamialahmadi T, Sahebkar A. SGLT2 inhibitors and autophagy in diabetes. Cell Biochemistry and Function. 2023;41(4):392-398. doi:10.1002/cbf.3792
BibTeX
@article{Yaribeygi2023,
author = {Yaribeygi, Habib and Maleki, Mina and Atkin, Stephen L and Jamialahmadi, Tannaz and Sahebkar, Amirhossein},
title = {SGLT2 inhibitors and autophagy in diabetes},
journal = {Cell Biochemistry and Function},
year = {2023},
volume = {41},
number = {4},
pages = {392--398},
doi = {10.1002/cbf.3792}
}
EUVIMED